EUVIMEDEUVIMED entdecken
Open Access

A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats

Fatma Kaya Dagistanli, Asli F Ceylan, Zubeyir Elmazoglu, Nigar Efendiyeva, Sanem Gülistan Sarıbaş, Belisa Kaleci Pilafi, Milan Stefek, Nuriye Nuray Ulusu, Çimen Karasu

Journal of Diabetes & Metabolic Disorders · 04.12.2025 · 24 (2)

DOI: 10.1007/s40200-025-01723-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes & Metabolic Disorders, online erschienen am 04.12.2025. Verfasst von Fatma Kaya Dagistanli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate the effects of cemtirestat, a promising drug candidate with both aldose reductase (AR) inhibitor (ARI) and antioxidant (AO) properties, on hepatic and pancreatic stress responses in rats, by comparing it with the ARI drug epalrestat and the antioxidant compound stobadine.

Methods

Two metabolic disorder models characterized by glycolipotoxicity were induced in rats by administering fructose alone (CF) or together with streptozotocin (DF). The rats were subsequently treated once daily for 14 weeks with either cemtirestat at two different doses (2.5, 7.5 mg/kg), the ARI drug epalrestat (25, 50 mg/kg), or antioxidant compound stobadine (25, 50 mg/kg).

Results

Liver enzymes (ALP, AST, ALT, and GGT) and oxidative stress markers (malondialdehyde, carbonyl, glutathione S-transferase, catalase) were elevated in both CF and DF compared to control rats (C). Cemtirestat, especially at the low dose, significantly prevented the noted abnormalities (except for ALT) and the increase in cholesterol in DF and the increase in triglycerides in CF. While epalrestat only partially prevented the decrease in the GSH to GSSG ratio, but cemtirestat and stobadine almost completely restored the ratio in both CF and DF models. However, histochemical and immunohistochemical analyses revealed that unlike epalrestat and stobadine, cemtirestat did not improve liver histopathology (PAS, Masson trichrome, TUNEL, PCNA and caspase-3 staining) and pancreatic histopathology (TUNEL, PCNA and caspase-3 staining), nor did it alleviate damage to insulin-, glucagon-, and somatostatin-secreting cells in the islets.

Conclusion

The findings may offer valuable insights that could facilitate the development of novel ARI/AO compounds and CMTI derivatives. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01723-4.

Schlagwörter

Stichwörter der Autor:innen

Aldose reductaseAntioxidantCemtirestatDiabetes mellitusEpalrestatFructoseMetabolic diseaseStobadine

Autor:innen und Institutionen

  • Department of Medical Biology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Department of Medical Pharmacology, Faculty of Medicine, Ankara Yildirim Beyazıt University, Ankara, Turkey.
  • Department of Pharmacology, Faculty of Pharmacy, Ankara Medipol University, Ankara, Turkey.
  • Department of Medical Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Department of Histology and Embryology, Faculty of Medicine, Health Sciences University Gulhane, Ankara, Turkey.
  • Medical University of Tirana, University Dental Clinic, Tiran, Albania.

Zitieren

APA

Dagistanli, F. K., Ceylan, A. F., Elmazoglu, Z., Efendiyeva, N., Sarıbaş, S. G., Pilafi, B. K., Stefek, M., Ulusu, N. N., & Karasu, Ç. (2025). A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats. Journal of Diabetes & Metabolic Disorders, 24(2). https://doi.org/10.1007/s40200-025-01723-4

Vancouver

Dagistanli FK, Ceylan AF, Elmazoglu Z, Efendiyeva N, Sarıbaş SG, Pilafi BK, et al. A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats. Journal of Diabetes & Metabolic Disorders. 2025;24(2). doi:10.1007/s40200-025-01723-4

BibTeX
@article{Dagistanli2025,
  author = {Dagistanli, Fatma Kaya and Ceylan, Asli F and Elmazoglu, Zubeyir and Efendiyeva, Nigar and Sarıbaş, Sanem Gülistan and Pilafi, Belisa Kaleci and Stefek, Milan and Ulusu, Nuriye Nuray and Karasu, Çimen},
  title = {A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats},
  journal = {Journal of Diabetes & Metabolic Disorders},
  year = {2025},
  volume = {24},
  number = {2},
  doi = {10.1007/s40200-025-01723-4}
}
Kostenlos starten →